IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18% - Zacks Investment Research
IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18% - Zacks Investment Research(摘要待生成)
ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates - Zacks Investment Research
ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates - Zacks Investment Research(摘要待生成)
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus - Yahoo Finance
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus - Yahoo Finance(摘要待生成)
Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy? The Motley Fool
IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss – Retail Says No Way To Escape Further Dilution - Yahoo Finance
IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss – Retail Says No Way To Escape Further Dilution - Yahoo Finance(摘要待生成)
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
The post ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million appeared first on ImmunityBio.
ImmunityBio, 8-K (2.02, 9.01): reported results of operations
ImmunityBio reported third-quarter 2026 net product revenue of $48.7 million, up 53% year over year, nine-month revenue of $143.6 million, up 92%, and FDA and Israeli approvals expanding ANKTIVA’s use in bladder cancer.
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026(摘要待生成)
$IBRX stock is down 25% today. Here's what we see in our data. | IBRX Stock News
$IBRX stock is down 25% today. Here's what we see in our data. Quiver Quantitative
Why is Immunitybio stock sliding today? - Investing.com
Why is Immunitybio stock sliding today? Investing.com
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
The post ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ appeared first on ImmunityBio.
ImmunityBio, 8-K (7.01, 9.01): Regulation FD disclosure
ImmunityBio said ANKTIVA plus BCG met the primary endpoint in its 370-patient QUILT-2.005 trial for BCG-naïve bladder cancer, with a statistically significant efficacy improvement versus BCG alone, and an FDA supplemental application remains on track by year-end 2026.
8-K - ImmunityBio, Inc. (0001326110) (Filer)
8-K - ImmunityBio, Inc. (0001326110) (Filer)(摘要待生成)